EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel

Ja Yoon Heo, Chung Lee, Heesun Shin, Sungmin Cho, Seung Hoon Beom, Young-Deuk Choi, Woong Kyu Han, Won Sik Ham, Won Sik Jang, Hyunho Han, Jongsoo Lee, Ji Eun Heo und 6 weitere

Cancer Investigation · 09.08.2026 · 44 (7) · 707-717

DOI: 10.1080/07357907.2026.2672004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Investigation, online erschienen am 15.05.2026. Verfasst von Ja Yoon Heo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Docetaxel, Tumor Suppressor Protein p53, Prostatic Neoplasms, Castration-Resistant, Retinoblastoma Binding Proteins. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Yonsei University College of Medicine Graduate School Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelTumor Suppressor Protein p53Prostatic Neoplasms, Castration-ResistantRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesAntineoplastic AgentsHumansMalePrognosisRetrospective StudiesAgedMiddle AgedAged, 80 and overMutationProgression-Free SurvivalBiomarkers, Tumor

Stichwörter der Autor:innen

BiomarkerCastration-resistant prostate cancerDocetaxelNext-generation sequencingRB1TP53

Substanzen

DocetaxelTumor Suppressor Protein p53RB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesTP53 protein, humanAntineoplastic AgentsBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Urology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Förderung

  • Yonsei University College of Medicine Graduate School Research Fund

Zitieren

APA

Heo, J. Y., Lee, C., Shin, H., Cho, S., Beom, S. H., Choi, Y. D., Han, W. K., Ham, W. S., Jang, W. S., Han, H., Lee, J., Heo, J. E., Khalaf, D., Emmenegger, U., Kim, S., Kim, C. G., Jung, M., & Shin, S. J. (2026). Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. Cancer Investigation, 44(7), 707-717. https://doi.org/10.1080/07357907.2026.2672004

Vancouver

Heo JY, Lee C, Shin H, Cho S, Beom SH, Choi YD, et al. Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. Cancer Investigation. 2026;44(7):707-717. doi:10.1080/07357907.2026.2672004

BibTeX
@article{Heo2026,
  author = {Heo, Ja Yoon and Lee, Chung and Shin, Heesun and Cho, Sungmin and Beom, Seung Hoon and Choi, Young-Deuk and Han, Woong Kyu and Ham, Won Sik and Jang, Won Sik and Han, Hyunho and Lee, Jongsoo and Heo, Ji Eun and Khalaf, Daniel and Emmenegger, Urban and Kim, Sangwoo and Kim, Chang Gon and Jung, Minsun and Shin, Sang Joon},
  title = {Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel},
  journal = {Cancer Investigation},
  year = {2026},
  volume = {44},
  number = {7},
  pages = {707--717},
  doi = {10.1080/07357907.2026.2672004}
}
Kostenlos starten →